Daphne Zohar is the founder and chief executive officer of PureTech and a member of the board of directors. She has also served as the founding chief executive officer of a number of PureTech’s Founded Entities. A successful entrepreneur, Ms. Zohar created PureTech, assembling a leading team to help implement her vision for the Company, and was a key participant in fundraising, business development and establishing the underlying programs and platforms that have resulted in PureTech’s substantial pipeline, which is comprised of 23 product candidates and one product that has been cleared by the US Food and Drug Administration. Ms. Zohar has been recognized as a top leader and innovator in biotechnology by a number of sources, including EY, BioWorld, MIT Technology Review, The Boston Globe and Scientific American. She is an editorial advisor to Xconomy, a US news company.

Joe Bolen, PhD, is chief scientific officer at PureTech, where he works with the Company’s discovery and preclinical team to identify and pursue promising new technologies. Dr. Bolen has more than 30 years of industry and research experience and has been at the forefront of cancer and immunology research. Dr. Bolen most recently oversaw all aspects of research and development for Moderna Therapeutics as president and chief scientific officer. Previously, he was chief scientific officer and global head of oncology research at Millennium: The Takeda Oncology Company. Prior to joining Millennium in 1999, Dr. Bolen held senior R&D positions at Hoechst Marion Roussel, Schering-Plough and Bristol-Myers Squibb. He began his career at the National Institutes of Health (NIH), where he contributed to the discovery of a class of proteins known as tyrosine kinase oncogenes as key regulators of the immune system. Dr. Bolen graduated from the University of Nebraska with a BS degree in microbiology and chemistry and a PhD in immunology and conducted his postdoctoral training in molecular virology at the Kansas State University Cancer Center.

Bharatt Chowrira, PhD, JD, has been the president and chief of business and strategy at PureTech since March 2017. Prior to joining PureTech, Dr. Chowrira was the president of Synlogic, Inc., a biopharmaceutical company focused on developing synthetic microbiome-based therapeutics, from September 2015 to February 2017, where he oversaw and managed corporate and business development, alliance management, financial, human resources, intellectual property and legal operations. Prior to joining Synlogic, Dr. Chowrira was the chief operating officer of Auspex Pharmaceuticals Inc., from 2013 to 2015, which was acquired by Teva Pharmaceuticals in the Spring of 2015. Previously, he was president and chief executive officer of Addex Therapeutics Ltd., a biotechnology company publicly traded on the SIX Swiss Exchange, from 2011 to 2013. Prior to that, Dr. Chowrira held various leadership and management positions at Nektar Therapeutics (chief operating officer), Merck & Co, or Merck (vice president), Sirna Therapeutics (general counsel; acquired by Merck) and Ribozyme Pharmaceuticals (chief patent counsel). Dr. Chowrira is a member of the board of directors of Vedanta Biosciences, Inc., and Vor Biopharma, Inc. Dr. Chowrira received a JD from the University of Denver’s Sturm College of Law, a PhD in molecular biology from the University of Vermont College of Medicine, an MS in molecular biology from Illinois State University and a BS in microbiology from the UAS, Bangalore, India.

Eric Elenko, PhD, is the chief innovation officer at PureTech where he has led the development of a number of programs, including Akili Interactive Labs, Inc., Gelesis, Inc., Karuna Therapeutics, Inc. and Sonde Health, Inc. Prior to joining PureTech, Dr. Elenko was a consultant with McKinsey and Company where he advised senior executives of both Fortune 500 and specialty pharmaceutical companies on a range of issues such as product licensing, mergers and acquisitions, research and development strategy and marketing. Dr. Elenko received his BA in biology from Swarthmore College and his PhD in biomedical sciences from the University of California, San Diego.

Joep Muijrers, PhD, is the chief of portfolio strategy at PureTech. Dr. Muijrers has two decades of experience in corporate and capital finance, specifically focused on investment, M&A, portfolio management, strategic asset allocation, financial and regulatory reporting and fundraising. Prior to joining PureTech, he was a portfolio manager and partner at LSP (Life Sciences Partners), a specialist investor group with sole focus on investing in healthcare and life sciences, in the Netherlands and in Boston. At LSP, Dr. Muijrers was responsible for investing in publicly traded companies, a strategy that generated a total return in excess of 900 percent, more than twice the return of the Nasdaq Biotechnology Index during the same period (Q2 2008 – Q1 2018). Notable investments included companies that were acquired by large pharma (Ablynx, CoLucid, InterMune, Kite Pharma, NeuroDerm) and/or became leaders in their respective areas of activity (Evotec, Genmab, GW Pharmaceuticals, MorphoSys, Neurocrine). Prior to joining LSP, he held the position of director corporate finance and capital markets at Fortis Bank, currently part of ABN AMRO. Dr. Muijrers is currently a member of the board of directors of Alivio Therapeutics, Inc., Entrega, Inc., Follica, Incorporated and Sonde Health, Inc. Dr. Muijrers holds a PhD degree in molecular biology from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and an MS in biochemistry from the University of Nijmegen, the Netherlands.

Stephen Muniz, Esq., is the chief operating officer at PureTech and has served as a member of PureTech’s board of directors since 2015. Prior to joining PureTech, Mr. Muniz was a partner in the corporate department of Locke Lord LLP, where he practiced law for 10 years. Mr. Muniz’s practice at Locke Lord LLP focused on the representation of life science venture funds as well as their portfolio companies in general corporate matters and in investment and liquidity transactions.

Prior to joining Locke Lord LLP, Mr Muniz was a law clerk to The Honorable Raya Dreben at the Massachusetts Appeals Court. He was also a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation. Mr. Muniz also sits on the board of directors of Entrega, Inc., Follica, Incorporated, and Alivio Therapeutics, Inc. He previously served on the board of directors of Karuna Therapeutics, Inc. and Gelesis, Inc. Mr. Muniz has a BA in economics and accounting from The College of the Holy Cross and a JD from the New England School of Law (NESL) where he graduated summa cum laude. Mr. Muniz was valedictorian of the 1997 NESL Commencement and has been awarded the Amos L. Taylor Award for Excellence in Scholarship, the New England Scholar Award and the NESL Trustee Scholar Award.

Spencer Ball is senior vice president of human resources at PureTech, where he leads staffing and recruitment strategies, leadership development, compensation and talent engagement. Prior to joining PureTech, Mr. Ball was director of talent acquisition and executive search for PARAXEL, where he managed PAREXEL's senior level recruiting efforts in the U.S. and Europe. Mr. Ball was also president of Ball & Company, Inc., a healthcare focused retainer based executive search firm, and vice president and managing director at J. Robert Scott, a wholly owned subsidiary of Fidelity Investments. Prior to that, Mr. Ball was associated with two regional executive search firms focused on healthcare and financial services. Mr. Ball received a BS in business administration from Bryant University.

Anne Burkhardt, PhD, is head of research at PureTech. Prior to joining PureTech, Dr. Burkhardt was a distinguished scientific fellow at Moderna Therapeutics. She held key positions within the research and development divisions at Millennium: The Takeda Oncology Company, DNAX Research Institute (Schering Plough), Merck & Co., Bristol Myers-Squibb and the National Institutes of Health (NIH). During her career, Dr. Burkhardt has led teams that have successfully progressed several small molecule therapeutics into the clinic and has been a contributing author on over 50 publications. She received a BA in biochemistry from Mount Holyoke College and a PhD in biochemistry from The University of Vermont.

Aleksandra Filipovic MD, PhD, is head of oncology at PureTech. Previously, Dr. Filipovic served as associate medical director of Bristol Myers Squibb (New York) for early phase oncology and immuno-oncology clinical trials. She graduated from medical school at the Faculty of Medicine University of Nis, Serbia, and completed her PhD on the identification and validation of novel therapeutic targets in breast cancer and monoclonal antibody drug development at Imperial College in London, UK. Following this, she received a Fellowship from the College for the continuation of the translational research work and continued clinical practice in medical oncology. Dr. Filipovic is also a practicing clinician at Imperial College NHS trust, faculty member at European School of Oncology, scientific committee member of Sharing Progress in Cancer Care (SPCC), associate editor for Frontiers in Oncology, and a member of American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), American Association for Cancer Research (AACR) and Society for Immunotherapy of Cancer (SITC).

Dilip Kodira is head of data science at PureTech, where he is responsible for building a strategic road map for accelerating PureTech’s data analysis and discovery capabilities with advanced machine learning and bioinformatics methods. Mr. Kodira has over 20 years of academic and industry experience leading high-profile data analysis efforts and research collaborations. Most recently, he was head of the Computational Biology & Modeling Group at GE Global Research Center. Mr. Kodira also held several leadership positions at Roche, Broad Institute and Celera Genomics, where he led the gene discovery efforts and cataloging of the genes in the first reference human genome. He is the author of over 50 publications in leading scientific journals. Mr. Kodira received an MS in molecular biology from Indiana State University and an MS in microbiology from University of Agricultural Sciences, Bangalore.

Brian Luchini is senior vice president of finance at PureTech. Prior to joining PureTech, Mr. Luchini was senior director of finance at Patheon by Thermo Fisher Scientific, where he supported Patheon’s $700 million IPO on the NYSE, the largest healthcare IPO of 2016, and the company’s acquisition by Thermo Fisher Scientific. Prior to Patheon, Mr. Luchini was senior director of financial planning and analysis for Fresenius Medical Care and served in roles of increasing responsibility at Raytheon Technologies. Mr. Luchini received an MBA from Bentley University and a bachelor's degree in finance from University of Massachusetts Amherst.

Allison Mead Talbot is head of communications at PureTech. Prior to joining PureTech, Ms. Talbot worked for two leading healthcare public relations firms, where she oversaw brand and corporate communications activities for clients including Novo Nordisk, Pfizer Inc., Novartis, Philips, Abbott Laboratories and ViiV Healthcare. Ms. Talbot was awarded the PR News Rising Star 30 and Under Award in 2014 and she received a BS in biotechnology and global health from the Georgetown University Edmund A. Walsh School of Foreign Service.

Cheryl Murphy, PhD, is head of grants management and strategy at PureTech. Under her leadership, PureTech and its Founded Entities have won several multi-million-dollar awards from the Department of Defense (DoD), National Institutes of Health (NIH) and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), among others. Prior to joining PureTech, Dr. Murphy was associate director for programs in psychiatric genetics and microbial genomics at the Broad Institute. Her career also includes research, business development and program management roles in the biotech industry, including at RiboNovix, Inc., Agenus (formerly Antigenics) and Aquila Biopharmaceuticals (acquired by Antigenics). She is the author of over 20 publications and an inventor on several patents. Dr. Murphy received a BA in biology and chemistry from Williams College and a PhD in microbiology from Duke University.

LuAnn Sabounjian is vice president of clinical operations at PureTech, where she also led the clinical development program at Alivio Therapeutics. Prior to joining PureTech, Ms. Sabounjian was vice president of clinical operations at Concert Pharmaceuticals, Inc., vice president of clinical development at Endo Pharmaceuticals Solutions Inc. (formerly Indevus Pharmaceuticals) and head of clinical operations and drug safety at PROMETRIKA, LLC. Throughout her career, Ms. Sabounjian has contributed to nine NDAs and brought seven drugs and two nutraceutical products to market. Ms. Sabounjian received her BS in nursing from Boston College and her MBA from University of Phoenix.

Anita Terpstra, PhD, JD, is senior vice president and head of intellectual property at PureTech. Prior to joining PureTech, Dr. Terpstra was associate general counsel at Synlogic Therapeutics. She also served as in-house counsel at Synlogic, Inc. and MilliporeSigma, and as partner and IP attorney at McDonnel Boehnen Hulbert & Berghoff LLP. Dr. Terpstra is a member of various Boston-based life sciences and IP groups, including Women in Bio and ChIPs (Chiefs in Intellectual Property). She received a JD from Saint Louis University School of Law, a PhD in molecular biology from Boston University and a BA in biology from Bates College.